Ionis Pharmaceuticals, Inc. (0JDI.L)
USD 26.5
(-3.21%)
USD 26.5
(-3.21%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 28.42 Million USD | 29.01% |
| 2022 | 22.03 Million USD | -11.18% |
| 2021 | 24.8 Million USD | 12.93% |
| 2020 | 21.96 Million USD | 20.82% |
| 2019 | 18.18 Million USD | 111.84% |
| 2018 | 8.58 Million USD | -14.03% |
| 2017 | 9.98 Million USD | 33.29% |
| 2016 | 7.48 Million USD | 8.55% |
| 2015 | 6.89 Million USD | 9.68% |
| 2014 | 6.29 Million USD | -21.7% |
| 2013 | 8.03 Million USD | 31.24% |
| 2012 | 6.12 Million USD | 47.89% |
| 2011 | 4.13 Million USD | 66.63% |
| 2010 | 2.48 Million USD | -10.26% |
| 2009 | 2.76 Million USD | 1.84% |
| 2008 | 2.71 Million USD | -3.51% |
| 2007 | 2.81 Million USD | 227.18% |
| 2006 | 861 Thousand USD | -9.46% |
| 2005 | 951 Thousand USD | -65.06% |
| 2004 | 2.72 Million USD | -80.55% |
| 2003 | 13.99 Million USD | 26.19% |
| 2002 | 11.09 Million USD | 0.0% |
| 2001 | - USD | 0.0% |
| 2000 | - USD | 0.0% |
| 1999 | - USD | 0.0% |
| 1998 | - USD | 0.0% |
| 1997 | - USD | 0.0% |
| 1996 | - USD | 0.0% |
| 1995 | - USD | 0.0% |
| 1994 | - USD | 0.0% |
| 1993 | - USD | 0.0% |
| 1992 | - USD | 0.0% |
| 1991 | - USD | 0.0% |
| 1990 | - USD | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q2 | 28.72 Million USD | -5.08% |
| 2024 Q1 | 30.25 Million USD | 6.45% |
| 2023 Q2 | 25.53 Million USD | 15.04% |
| 2023 FY | 28.42 Million USD | 29.01% |
| 2023 Q3 | 25.63 Million USD | 0.38% |
| 2023 Q4 | 28.42 Million USD | 10.89% |
| 2023 Q1 | 22.2 Million USD | 0.76% |
| 2022 Q2 | 19.81 Million USD | -17.56% |
| 2022 FY | 22.03 Million USD | -11.18% |
| 2022 Q1 | 24.03 Million USD | -3.12% |
| 2022 Q4 | 22.03 Million USD | 6.72% |
| 2022 Q3 | 20.64 Million USD | 4.21% |
| 2021 FY | 24.8 Million USD | 12.93% |
| 2021 Q1 | 22.19 Million USD | 1.07% |
| 2021 Q4 | 24.8 Million USD | 8.18% |
| 2021 Q2 | 24.09 Million USD | 8.56% |
| 2021 Q3 | 22.93 Million USD | -4.85% |
| 2020 Q4 | 21.96 Million USD | -0.93% |
| 2020 Q1 | 22.88 Million USD | 25.88% |
| 2020 FY | 21.96 Million USD | 20.82% |
| 2020 Q2 | 23.72 Million USD | 3.66% |
| 2020 Q3 | 22.17 Million USD | -6.53% |
| 2019 Q2 | 18.5 Million USD | 67.36% |
| 2019 Q3 | 19.37 Million USD | 4.7% |
| 2019 Q4 | 18.18 Million USD | -6.17% |
| 2019 FY | 18.18 Million USD | 111.84% |
| 2019 Q1 | 11.05 Million USD | 28.84% |
| 2018 Q3 | 8.37 Million USD | -7.6% |
| 2018 Q4 | 8.58 Million USD | 2.43% |
| 2018 FY | 8.58 Million USD | -14.03% |
| 2018 Q1 | 9.06 Million USD | -9.24% |
| 2018 Q2 | 9.06 Million USD | 0.08% |
| 2017 Q2 | 6.5 Million USD | -4.37% |
| 2017 Q3 | 8.45 Million USD | 29.94% |
| 2017 Q4 | 9.98 Million USD | 18.12% |
| 2017 FY | 9.98 Million USD | 33.29% |
| 2017 Q1 | 6.8 Million USD | -9.19% |
| 2016 Q4 | 7.48 Million USD | -19.64% |
| 2016 FY | 7.48 Million USD | 8.55% |
| 2016 Q1 | 6.52 Million USD | -5.49% |
| 2016 Q2 | 7.66 Million USD | 17.61% |
| 2016 Q3 | 9.31 Million USD | 21.53% |
| 2015 Q3 | 6.58 Million USD | -2.93% |
| 2015 Q4 | 6.89 Million USD | 4.8% |
| 2015 Q1 | 6.83 Million USD | 8.73% |
| 2015 FY | 6.89 Million USD | 9.68% |
| 2015 Q2 | 6.78 Million USD | -0.83% |
| 2014 Q3 | 7.08 Million USD | -8.89% |
| 2014 Q2 | 7.77 Million USD | 3.17% |
| 2014 Q1 | 7.53 Million USD | -6.17% |
| 2014 FY | 6.29 Million USD | -21.7% |
| 2014 Q4 | 6.29 Million USD | -11.22% |
| 2013 Q4 | 8.03 Million USD | 8.77% |
| 2013 Q2 | 8.3 Million USD | 43.04% |
| 2013 Q1 | 5.8 Million USD | -5.1% |
| 2013 FY | 8.03 Million USD | 31.24% |
| 2013 Q3 | 7.38 Million USD | -11.12% |
| 2012 Q1 | 4.87 Million USD | 17.73% |
| 2012 Q3 | 6.73 Million USD | -5.22% |
| 2012 Q4 | 6.12 Million USD | -9.14% |
| 2012 Q2 | 7.1 Million USD | 45.86% |
| 2012 FY | 6.12 Million USD | 47.89% |
| 2011 Q1 | 2.6 Million USD | 4.91% |
| 2011 FY | 4.13 Million USD | 66.63% |
| 2011 Q3 | 2.91 Million USD | 29.61% |
| 2011 Q2 | 2.24 Million USD | -13.7% |
| 2011 Q4 | 4.13 Million USD | 41.99% |
| 2010 Q3 | 1.99 Million USD | -28.56% |
| 2010 Q2 | 2.79 Million USD | 7.42% |
| 2010 Q1 | 2.6 Million USD | -6.03% |
| 2010 FY | 2.48 Million USD | -10.26% |
| 2010 Q4 | 2.48 Million USD | 24.45% |
| 2009 Q3 | 2.81 Million USD | 1.37% |
| 2009 Q1 | 2.59 Million USD | -4.67% |
| 2009 FY | 2.76 Million USD | 1.84% |
| 2009 Q2 | 2.77 Million USD | 7.26% |
| 2009 Q4 | 2.76 Million USD | -1.74% |
| 2008 Q3 | 5.51 Million USD | 17.28% |
| 2008 Q4 | 2.71 Million USD | -50.68% |
| 2008 FY | 2.71 Million USD | -3.51% |
| 2008 Q1 | 3.7 Million USD | 31.35% |
| 2008 Q2 | 4.69 Million USD | 27.0% |
| 2007 FY | 2.81 Million USD | 227.18% |
| 2007 Q1 | 1.09 Million USD | 26.95% |
| 2007 Q2 | 1.51 Million USD | 38.15% |
| 2007 Q3 | 1.93 Million USD | 27.81% |
| 2007 Q4 | 2.81 Million USD | 45.96% |
| 2006 FY | 861 Thousand USD | -9.46% |
| 2006 Q1 | 749 Thousand USD | -21.24% |
| 2006 Q2 | 886 Thousand USD | 18.29% |
| 2006 Q3 | 632 Thousand USD | -28.67% |
| 2006 Q4 | 861 Thousand USD | 36.23% |
| 2005 Q4 | 951 Thousand USD | 3.71% |
| 2005 Q3 | 917 Thousand USD | -14.38% |
| 2005 Q2 | 1.07 Million USD | -60.65% |
| 2005 Q1 | 2.72 Million USD | 0.0% |
| 2005 FY | 951 Thousand USD | -65.06% |
| 2004 Q4 | 2.72 Million USD | -86.45% |
| 2004 FY | 2.72 Million USD | -80.55% |
| 2004 Q3 | 20.09 Million USD | 24.98% |
| 2004 Q2 | 16.07 Million USD | 10.49% |
| 2004 Q1 | 14.54 Million USD | 3.95% |
| 2003 Q2 | 6.56 Million USD | -54.62% |
| 2003 Q3 | 9.29 Million USD | 41.58% |
| 2003 FY | 13.99 Million USD | 26.19% |
| 2003 Q1 | 14.46 Million USD | 30.41% |
| 2003 Q4 | 13.99 Million USD | 50.6% |
| 2002 Q2 | - USD | 0.0% |
| 2002 Q1 | - USD | 0.0% |
| 2002 FY | 11.09 Million USD | 0.0% |
| 2002 Q4 | 11.09 Million USD | -15.18% |
| 2002 Q3 | 13.07 Million USD | 0.0% |
| 2001 Q1 | - USD | 0.0% |
| 2001 Q4 | - USD | 0.0% |
| 2001 Q3 | - USD | 0.0% |
| 2001 Q2 | - USD | 0.0% |
| 2001 FY | - USD | 0.0% |
| 2000 Q3 | - USD | 0.0% |
| 2000 FY | - USD | 0.0% |
| 2000 Q2 | - USD | 0.0% |
| 2000 Q1 | - USD | 0.0% |
| 2000 Q4 | - USD | 0.0% |
| 1999 Q1 | - USD | 0.0% |
| 1999 Q4 | - USD | 0.0% |
| 1999 FY | - USD | 0.0% |
| 1999 Q3 | - USD | 0.0% |
| 1999 Q2 | - USD | 0.0% |
| 1998 FY | - USD | 0.0% |
| 1998 Q4 | - USD | 0.0% |
| 1998 Q3 | - USD | 0.0% |
| 1998 Q2 | - USD | 0.0% |
| 1998 Q1 | - USD | 0.0% |
| 1997 Q3 | - USD | 0.0% |
| 1997 FY | - USD | 0.0% |
| 1997 Q1 | - USD | 0.0% |
| 1997 Q4 | - USD | 0.0% |
| 1997 Q2 | - USD | 0.0% |
| 1996 FY | - USD | 0.0% |
| 1996 Q4 | - USD | 0.0% |
| 1996 Q1 | - USD | 0.0% |
| 1996 Q2 | - USD | 0.0% |
| 1996 Q3 | - USD | 0.0% |
| 1995 Q3 | - USD | 0.0% |
| 1995 Q1 | - USD | 0.0% |
| 1995 Q4 | - USD | 0.0% |
| 1995 FY | - USD | 0.0% |
| 1995 Q2 | - USD | 0.0% |
| 1994 FY | - USD | 0.0% |
| 1994 Q1 | - USD | 0.0% |
| 1994 Q3 | - USD | 0.0% |
| 1994 Q4 | - USD | 0.0% |
| 1994 Q2 | - USD | 0.0% |
| 1993 FY | - USD | 0.0% |
| 1993 Q1 | - USD | 0.0% |
| 1993 Q2 | - USD | 0.0% |
| 1993 Q3 | - USD | 0.0% |
| 1993 Q4 | - USD | 0.0% |
| 1992 FY | - USD | 0.0% |
| 1992 Q4 | - USD | 0.0% |
| 1992 Q1 | - USD | 0.0% |
| 1992 Q2 | - USD | 0.0% |
| 1992 Q3 | - USD | 0.0% |
| 1991 Q1 | - USD | 0.0% |
| 1991 Q4 | - USD | 0.0% |
| 1991 FY | - USD | 0.0% |
| 1991 Q3 | - USD | 0.0% |
| 1991 Q2 | - USD | 0.0% |
| 1990 Q4 | - USD | 0.0% |
| 1990 FY | - USD | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| uniQure N.V. | 12.02 Million USD | -136.402% |
| Agios Pharmaceuticals, Inc. | 19.07 Million USD | -49.009% |
| Amicus Therapeutics, Inc. | 59.69 Million USD | 52.384% |
| Atara Biotherapeutics, Inc. | 9.7 Million USD | -192.86% |
| bluebird bio, Inc. | 22.91 Million USD | -24.024% |
| Cara Therapeutics, Inc. | 2.82 Million USD | -907.621% |
| Imunon, Inc. | - USD | -Infinity% |
| Editas Medicine, Inc. | - USD | -Infinity% |
| IQVIA Holdings Inc. | - USD | -Infinity% |
| Mettler-Toledo International Inc. | 385.86 Million USD | 92.633% |
| Myriad Genetics, Inc. | 20.1 Million USD | -41.418% |
| Neurocrine Biosciences, Inc. | 38.3 Million USD | 25.783% |
| Supernus Pharmaceuticals, Inc. | 77.4 Million USD | 63.279% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 8.32 Billion USD | 99.658% |
| Waters Corporation | 516.23 Million USD | 94.494% |
| Thermo Fisher Scientific Inc. | 5.08 Billion USD | 99.441% |
| Biogen Inc. | 2.52 Billion USD | 98.875% |
| Nektar Therapeutics | 16.1 Million USD | -76.542% |
| Perrigo Company plc | 1.14 Billion USD | 97.509% |
| Dynavax Technologies Corporation | 53.29 Million USD | 46.66% |
| Illumina, Inc. | 587 Million USD | 95.158% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 10.37 Million USD | -174.055% |
| Heron Therapeutics, Inc. | 42.11 Million USD | 32.498% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 1.1 Billion USD | 97.433% |
| Sangamo Therapeutics, Inc. | - USD | -Infinity% |
| Evolus, Inc. | 10.99 Million USD | -158.456% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | - USD | -Infinity% |
| Regeneron Pharmaceuticals, Inc. | 2.58 Billion USD | 98.898% |
| Esperion Therapeutics, Inc. | 65.62 Million USD | 56.684% |
| FibroGen, Inc. | 41.56 Million USD | 31.613% |
| Agilent Technologies, Inc. | 1.03 Billion USD | 97.243% |
| OPKO Health, Inc. | 65.69 Million USD | 56.733% |
| Homology Medicines, Inc. | - USD | -Infinity% |
| Geron Corporation | - USD | -Infinity% |
| Alnylam Pharmaceuticals, Inc. | 89.14 Million USD | 68.114% |
| Exelixis, Inc. | 17.32 Million USD | -64.088% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | - USD | -Infinity% |
| Zoetis Inc. | 2.56 Billion USD | 98.891% |
| Axsome Therapeutics, Inc. | 15.13 Million USD | -87.81% |
| Abeona Therapeutics Inc. | -2.44 Million USD | 1263.052% |
| Vertex Pharmaceuticals Incorporated | 738.8 Million USD | 96.153% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sarepta Therapeutics, Inc. | 322.85 Million USD | 91.196% |
| Corcept Therapeutics Incorporated | 7.73 Million USD | -267.723% |
| Halozyme Therapeutics, Inc. | 127.6 Million USD | 77.724% |
| Blueprint Medicines Corporation | 21.22 Million USD | -33.935% |
| Insmed Incorporated | 83.24 Million USD | 65.855% |
| TG Therapeutics, Inc. | 39.82 Million USD | 28.622% |
| Incyte Corporation | 62.97 Million USD | 54.861% |
| Emergent BioSolutions Inc. | 328.9 Million USD | 91.358% |